Grant of Options
Transense Technologies plc announced the grant of 100,000 share options to its Managing Director, Ryan Maughan, at an exercise price of 10 pence per share, with vesting contingent on the share price reaching 150 pence for ten consecutive trading days for two-thirds of the options and 200 pence for the remaining third. Following this, Mr. Maughan holds a total of 450,000 options. Additionally, 205,000 options were granted to other employees, bringing the total outstanding options to 1,895,000, representing approximately 11.53% of the issued share capital, well within the permitted 15% headroom.
Select text to share a quote on X · sign in to keep highlights & notes in your TRT notes
Transense Technologies plc (AIM: TRT), the provider of specialist sensor technology and measurement systems, announces that on 12 May 2026, the Company's remuneration committee (the "Remuneration Committee") approved the grant of 100,000 share options (the "Options") to acquire ordinary shares of 10 pence each in the Company ("Ordinary Shares") to Ryan Maughan, the Company's Managing Director.
In accordance with the Company's share scheme, the Options are subject to performance criteria and have an exercise price of 10 pence per share, being nominal value, and can be exercised after three years until the tenth anniversary of the grant. Two thirds of the Options are exercisable if the Company's share price reaches or exceeds 150 pence per share for ten consecutive trading days at any time, and no Options are exercisable unless this is achieved. The remaining third are exercisable, in full, if the share price reaches or exceeds 200 pence per share for ten consecutive trading days at any time. None of this tranche is exercisable if the share price has not reached 150 pence per share for ten consecutive trading days and a pro‐rata amount will be exercisable between these two share price targets.
Following this grant, Ryan Maughan is now interested in a total of 450,000 share options in the Company.
205,000 additional Options have been granted to other employees on the same basis. Following these grants, the Company has a total of 1,895,000 options outstanding, representing approximately 11.53% of the Company's issued share capital.
The Company's remuneration policy approved by shareholders by an advisory vote at the Annual General Meeting in November 2024 permits overall headroom for the grant of share options of 15% of the issued share capital in any ten year period.
| Cavendish Capital Market Limited (Nominated Adviser and Broker) Adrian Hadden / Callum Davidson (Corporate Finance) Jasper Berry (Sales) | 0207 220 0500 | |
| Investor Relations Anice McNamee | Tel: +44 (0)1869 238380 Investor.relations@transense.co.uk | |
| Find out more at: https://www.transense.com/ | ||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Ryan Maughan |
| 2 | Reason for the notification | |
| a) | Position/status | Managing Director |
| b) | Initial notification /Amendment | Initial |
| a) | Name | Transense Technologies plc |
| b) | LEI | 2138005N52J6KKQ3EY67 |
| a) | Description of the financial instrument, type of instrument | Options over Ordinary shares of 10 pence each |
| Identification code | GB00BDHDTH21 | |
| b) | Nature of the transaction | Grant of options |
| c) | Price and volume | Exercise Price(s) 10p Volume(s) 100,000 |
| d) | Aggregated information | |
| - Aggregated volume | As above | |
| - Price | ||
| e) | Date of the transaction | 12 May 2026 |
| f) | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.